Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9

Xenobiotica

Volumn 42, Issue 10, 2012, Pages 1001-1008

  Zhu, Liangliang ^a,b   Ge, Guangbo ^a   Liu, Yong ^a   He, Guiyuan ^a,b   Liang, Sicheng ^a   Fang, Zhongze ^a,b   Dong, Peipei ^c   Cao, Yunfeng ^a   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Glucuronidation; Magnolol; UDP glucuronosyltransferases; UGT inhibitor

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; MAGNOLOL;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME;

BIOCATALYSIS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; ENZYME INHIBITORS; GASTROINTESTINAL TRACT; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIGNANS; MICROSOMES, LIVER; RECOMBINANT PROTEINS;

EID: 84865841144     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.681814     Document Type: Article

References (29)

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
2. Chen YH, Lin FY, Liu PL, Huang YT, Chiu JH, Chang YC, Man KM, Hong CY, Ho YY, Lai MT. (2009). Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res 32:221-228.
3. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ. (2003). Evaluation of 3'-azido-3'- deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7 2 polymorphism. Drug Metab Dispos 31:1125-1133.
4. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. (2002). Characterization of benzo(a)pyrene-trans- 7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978-1986.
6. Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B. (2003). Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica 33:1073-1083.
7. Greenberg M, Urnezis P, Tian M. (2007). Compressed mints and chewing gum containing magnolia bark extract are effective against bacteria responsible for oral malodor. J Agric Food Chem 55:9465-9469.
8. Homma M, Oka K, Kobayashi H, Niitsuma T, Yamamoto S, Itoh H, Takahashi N. (1993). Liquid chromatographic determination of magnolol in urine collected from volunteers after a single dose of saiboku-to, an oriental herbal medicine for bronchial asthma. J Pharm Pharmacol 45:839-841.
9. Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
10. Lautala P, Ethell BT, Taskinen J, Burchell B. (2000). The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385-1389.
11. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. (2011). Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther 130:157-176.
12. Lee DH, Szczepanski MJ, Lee YJ. (2009). Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem 106:1113-1122.
13. Lin SP, Tsai SY, Lee Chao PD, Chen YC, Hou YC. (2011). Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med 77:1800-1805.
14. Liu Y, Ramírez J, House L, Ratain MJ. (2010). Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32-39.
15. Mano Y, Usui T, Kamimura H. (2006). Identification of human UDPglucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm Res 23:1502-1508.
16. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, Knights KM. (2011). Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644-652.
17. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S. (2006). Kinetics of acetaminophen glucuronidation by UDPglucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol 19:701-709.
18. Nagar S, Remmel RP. (2006). Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672.
19. Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptasepolymerase chain reaction. Drug Metab Dispos 37:32-40.
20. Park J, Lee J, Jung E, Park Y, Kim K, Park B, Jung K, Park E, Kim J, Park D. (2004). In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur J Pharmacol 496:189-195.
21. Ramírez J, Iyer L, Journault K, Bélanger P, Innocenti F, Ratain MJ, Guillemette C. (2002). In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 19:588-594.
22. Soars MG, Ring BJ, Wrighton SA. (2003). The effect of incubation conditions on the enzyme kinetics of UDPglucuronosyltransferases. Drug Metab Dispos 31:762-767.
23. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDPglucuronosyltransferases. Drug Metab Dispos 34:449-456.
24. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. (2004). Human UDPglucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
25. Wang JP, Ho TF, Chang LC, Chen CC. (1995). Anti-inflammatory effect of magnolol, isolated from Magnolia officinalis, on A23187-induced pleurisy in mice. J Pharm Pharmacol 47:857-860.
26. Zaya MJ, Hines RN, Stevens JC. (2006). Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 34:2097-2101.
27. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. (2005). In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-1739.
28. Zhu L, Ge G, Zhang H, Liu H, He G, Liang S, Zhang Y, Fang Z, Dong P, Finel M, Yang L. (2012). Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDPglucuronosyltransferase isoforms. Drug Metab Dispos 40:529-538.
29. Zhou J, Tracy TS, Remmel RP. (2010). Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP- glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38:431-440.